According to filings with the U.S. Securities and Exchange Commission, Emit Imaging is raising $5,878,666.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Matthew Silva played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Emit Imaging
Emit enables discovery by bridging the gap between in vivo imaging and pathology. Our technology uniquely enables high resolution imaging combined with a whole body comprehensive 3D data set. This technology can dramatically increase the value of each sample in a multi modal study. Our system is used in many research and discovery applications including: 1. Pharmacokinetics/Pharmacodynamics 2. Phenotyping and model development 3. Biodistribution/Bioavailability 4. Gene Expression 5. Cell tracking/ Regenerative medicine 6. Clinical molecular pathology The Emit Imaging system is a high throughput whole organ/body sectioning and imaging system which produces a 3D fluorescence and corresponding anatomical data set. Powerful reconstruction and analysis tools are then used to report levels and location of target fluorescence throughout the tissue.

To learn more about Emit Imaging, visit http://www.emitimaging.com/

Contact:
Matthew Silva, Chief Executive Officer
617-959-0099

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.